Antiproliferative Noscapinoids Bearing an Amidothiadiazole Scaffold as Apoptosis Inducers: Design, Synthesis and...

Noscapine an FDA-approved antitussive agent. With low cytotoxicity with higher concentrations, noscapine and its derivatives have been shown to have exceptional anticancer properties against a variety of cancer cell lines. In order to increase its potency, in this study, we synthesized a series of new amido-thiadiazol coupled noscapinoids and tested their cytotoxicity in vitro. All of the newly synthesised compounds demonstrated potent cytotoxic potential, with IC₅₀ values ranging from 2.1 to 61.2 μM than the lead molecule, noscapine (IC₅₀ value ranges from 31 to 65.5 μM) across all cell lines, without affecting normal cells (IC₅₀ value is>300 μM). Molecular docking of all these molecules with tubulin (PDB ID: 6Y6D, resolution 2.20 Å) also revealed better binding affinity (docking score range from -5.418 to -9.679 kcal/mol) compared to noscapine (docking score is -5.304 kcal/mol). One of the most promising synthetic derivatives 6aa (IC₅₀ value ranges from 2.5 to 7.3 μM) was found to bind tubulin with the highest binding affinity (ΔG_binding is -28.97 kcal/mol) and induced apoptosis in cancer cells more effectively.